Study Examines the Power of Biopharma and Patient Advocacy Partnerships in Drug Development

Conference breakout session examines the role of strategic partnerships in driving progress for sexual and gender minority inclusion in clinical research.

Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.

Conference keynote explores the long-term vision for integrating clinical research and care by 2035, including progress driven by digital advancements, artificial intelligence, and evolving regulatory frameworks.

The top five episodes of our podcast in the year 2024, highlighted.

Braftovi (encorafenib) plus Erbitux (cetuximab) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) improved progression-free survival and overall survival compared to chemotherapy in patients with metastatic colorectal cancer with a BRAF V600E mutation.

A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.